Ionis has released a recent Community Statement to the AxD community
The statement includes updates on their zilganersen program, including the implementation of a protocol amendment to extend access for clinical trial participants, the presentation of additional trial results at a medical conference, and their work to advance access to zilganersen for people with Alexander disease (AxD) in regions outside the US.
“We are working to enable the import/export of zilganersen outside the US, compiling and formatting clinical trial information to support a partner’s future regulatory filings, and collecting data on patient numbers, diagnostic centers, care sites, and interest in zilganersen among the global AxD community.”
To read: Ionis Community Statement
